drugset / Trial / NCT02718755
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if fludarabine, cytarabine (ARA-C), and erwinase (also known as asparaginase \[erwinia\]) in combination can help to control relapsed or refractory hematologic malignancies. The safety of these drugs will also be studied.
Timeline
- Start
- 2018-05
- Primary completion
- 2021-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asparaginase Erwinia chrysanthemi | Protein / enzyme biologic | 25000 unknown | Intravenous |
| Subject | Cytarabine | Small molecule | 2 g | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |